Sanofi

Research Sanofi (SNY) on Bullrun: market cap USD 112.24B, dividend yield 5.4%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 112.24B; dividend yield is 5.4%.

Peer valuation comparison

Latest dividend yield is 5.4% versus a Healthcare sector median of 2.11% (155.9% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025EUR 46.72BEUR 7.81BEUR 7.21B72.1%5.26EUR 7.66BEUR 20.33BEUR 71.38B
FY2024EUR 41.71BEUR 5.56Bn/a70.5%3.54EUR 7.44BEUR 17.91BEUR 77.51B
FY2023n/an/an/an/a2.17EUR 8.71BEUR 18.42BEUR 74.04B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 112.24Bn/a5.3%2.42
20252025-12-31USD 118.19Bn/a4.6%2.21
20242024-12-31USD 120.92Bn/a4.2%2.04
20232023-12-29USD 124.72Bn/a3.8%1.9
20222022-12-30USD 121.47Bn/a4.2%2.05
20212021-12-31USD 125.50Bn/a3.8%1.91

Dividend history

Latest trailing dividend snapshot: annual dividend/share 2.42 USD, yield 5.4%.

About Sanofi

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Sanofi's market cap?

Sanofi's market capitalization is USD 112.24B.

Does Sanofi pay a dividend?

Sanofi has a dividend yield of 5.4%.

What does Sanofi do?

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc.